跳至主要内容
临床试验/EUCTR2011-005693-36-IT
EUCTR2011-005693-36-IT进行中(未招募)不适用

Intraepithelial neoplasia detection rate after single oral dose of methylene blue MMX modified release tablets administered to patients with long standing ulcerative colitis undergoing colonoscopy - NA

COSMO TECHNOLOGIES LTD0 个研究点开始时间: 2012年3月2日最近更新:
适应症

试验速览

阶段
不适用
状态
进行中(未招募)

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional clinical trial of medicinal product

入排标准

性别
All

入选标准

  • male and Female patients, aged more than 18 years, affected by Long standing ulcerative colitis for more than 8 years. informed consent signed.
  • Are the trial subjects under 18? no
  • Number of subjects for this age range: 0
  • F.1.2 Adults (18-64 years) yes
  • F.1.2.1 Number of subjects for this age range 80
  • F.1.3 Elderly (>=65 years) yes
  • F.1.3.1 Number of subjects for this age range 20

排除标准

  • Pregnancy, allergies, diseases: known or suspected gastrointestinal obstruction or perforation, toxic megacolon, major colonic resection, severe diverticulosis with diverticulitis, heart failure, serious cardiovascular disease, severe liver failure, end-stage renal insufficiency. Presence of intraepithelial tumors. coagulation alterations.

研究者

相似试验